New drug combo aims to boost immune attack on liver cancer
NCT ID NCT03680508
First seen Apr 05, 2026 · Last updated May 22, 2026 · Updated 9 times
Summary
This study tests whether two drugs (cobolimab and dostarlimab) can help the immune system fight advanced liver cancer. About 42 adults with liver cancer that cannot be removed by surgery will receive the combination. The main goal is to see how many patients' tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ADULT PRIMARY LIVER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Oregon Health & Science University Knight Cancer Institute
Portland, Oregon, 97239, United States
-
University of Hawaii
Honolulu, Hawaii, 96813, United States
Conditions
Explore the condition pages connected to this study.